Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

– Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent... | May 16, 2023

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Steven Nichtberger ,Sarah Mccabe ,Anup Marda ,Drug Administration ,Exchange Commission ,Stern Investor Relations Inc ,Nasdaq ,Cabaletta Bio Inc ,Lancet Rheumatology ,Investigational New Drug ,Chief Executive Officer ,Cabaletta Bio ,Private Securities Litigation Reform Act ,Orphan Drug Designation ,Fast Track Designation ,Investor Relations ,Nc Stock Exchange ,News ,Information ,Press Release ,Trial ,Or ,Planned ,O ,Nitiate ,N ,Patients ,Ith ,Myositis ,It ,Nitial ,Nose ,Hat ,Us ,Equivalent ,The ,Ased ,Patient ,Eported ,He Caba Us12674w1099 ,